Intrexon Corp (NYSE:XON) saw some unusual options trading on Monday. Stock investors purchased 3,153 put options on the stock. This is an increase of 3,699% compared to the typical daily volume of 83 put options.

Several brokerages have recently issued reports on XON. ValuEngine raised Intrexon from a “sell” rating to a “hold” rating in a research report on Monday. Zacks Investment Research raised Intrexon from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Thursday, August 16th. Stifel Nicolaus began coverage on Intrexon in a research report on Tuesday, July 17th. They issued a “buy” rating and a $72.00 price target on the stock. Finally, Bank of America downgraded Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 price target on the stock. in a research report on Monday, July 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $33.14.

XON stock opened at $19.07 on Tuesday. Intrexon has a twelve month low of $10.26 and a twelve month high of $20.49. The stock has a market cap of $1.87 billion, a P/E ratio of -20.73 and a beta of 1.09. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.53 and a current ratio of 1.78.

Intrexon (NYSE:XON) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.28). Intrexon had a negative return on equity of 16.67% and a negative net margin of 82.17%. The firm had revenue of $45.30 million for the quarter, compared to analyst estimates of $51.70 million. During the same period last year, the business earned ($0.16) earnings per share. sell-side analysts predict that Intrexon will post -0.79 earnings per share for the current fiscal year.

In other Intrexon news, CEO Randal J. Kirk purchased 7,479,431 shares of the stock in a transaction dated Tuesday, July 3rd. The shares were bought at an average cost of $13.37 per share, with a total value of $99,999,992.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Helen Sabzevari sold 8,402 shares of the firm’s stock in a transaction dated Wednesday, July 18th. The shares were sold at an average price of $14.54, for a total value of $122,165.08. Following the completion of the sale, the insider now directly owns 25,000 shares in the company, valued at $363,500. The disclosure for this sale can be found here. Company insiders own 48.20% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. Peregrine Capital Management LLC boosted its holdings in Intrexon by 15.7% during the second quarter. Peregrine Capital Management LLC now owns 711,266 shares of the biotechnology company’s stock valued at $9,915,000 after purchasing an additional 96,393 shares in the last quarter. Wellington Shields & Co. LLC raised its stake in shares of Intrexon by 9.7% in the second quarter. Wellington Shields & Co. LLC now owns 335,600 shares of the biotechnology company’s stock valued at $4,678,000 after acquiring an additional 29,600 shares during the last quarter. Northern Trust Corp raised its stake in shares of Intrexon by 9.7% in the first quarter. Northern Trust Corp now owns 411,324 shares of the biotechnology company’s stock valued at $6,305,000 after acquiring an additional 36,508 shares during the last quarter. Chessman Wealth Strategies RIA bought a new position in shares of Intrexon in the second quarter valued at approximately $205,000. Finally, Millennium Management LLC raised its stake in shares of Intrexon by 203.2% in the first quarter. Millennium Management LLC now owns 298,737 shares of the biotechnology company’s stock valued at $4,580,000 after acquiring an additional 200,193 shares during the last quarter. 84.92% of the stock is currently owned by institutional investors and hedge funds.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Further Reading: Market Capitalization

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.